Determination of the Prognostic and Predictive Value of the Cancer Antigen-125 (CA-125) Marker in Lung Cancer Monitoring
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- E-DA Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- The diagnostic Value of the cancer antigen-125 in lung cancer
- Last Updated
- 10 years ago
Overview
Brief Summary
The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura.
The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically proved lung cancer
Exclusion Criteria
- •History of other cancers within the past 5 years
- •Pregnancy or breast milk feeding
- •TB pleuritis and peritonitis
Outcomes
Primary Outcomes
The diagnostic Value of the cancer antigen-125 in lung cancer
Time Frame: 12months
1. Comparison of CA-125 level in serum between lung cancer patients with or without malignant pleural effusion 2. The correlation between serum and pleural effusion CA-125 level
Secondary Outcomes
- The prognostic value of the cancer antigen-125 in lung cancer(24 months)